Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Price Down 4.8% – What’s Next?

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) was down 4.8% on Monday . The stock traded as low as $4.19 and last traded at $4.19. Approximately 97,282 shares traded hands during mid-day trading, a decline of 97% from the average daily volume of 3,049,515 shares. The stock had previously closed at $4.40.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the company. Capital One Financial downgraded Ironwood Pharmaceuticals from an “overweight” rating to an “equal weight” rating and dropped their price objective for the company from $12.00 to $4.00 in a report on Thursday, August 8th. StockNews.com raised shares of Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, July 16th. Leerink Partners began coverage on shares of Ironwood Pharmaceuticals in a research report on Monday, September 9th. They set a “market perform” rating and a $5.00 price target on the stock. Leerink Partnrs upgraded Ironwood Pharmaceuticals to a “hold” rating in a research note on Monday, September 9th. Finally, Wells Fargo & Company dropped their price objective on Ironwood Pharmaceuticals from $14.00 to $12.00 and set an “overweight” rating on the stock in a research note on Friday, August 9th. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $12.17.

Ironwood Pharmaceuticals Trading Down 5.0 %

The firm has a market cap of $654.29 million, a price-to-earnings ratio of -0.61 and a beta of 0.48. The firm’s 50 day simple moving average is $4.46 and its two-hundred day simple moving average is $5.97.

Insider Buying and Selling

In related news, insider Minardo John sold 9,910 shares of the business’s stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $4.27, for a total value of $42,315.70. Following the completion of the transaction, the insider now owns 284,661 shares of the company’s stock, valued at $1,215,502.47. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 12.90% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. Everence Capital Management Inc. raised its position in Ironwood Pharmaceuticals by 36.3% in the third quarter. Everence Capital Management Inc. now owns 27,850 shares of the biotechnology company’s stock valued at $115,000 after purchasing an additional 7,420 shares during the last quarter. Creative Planning boosted its position in Ironwood Pharmaceuticals by 12.7% in the third quarter. Creative Planning now owns 42,151 shares of the biotechnology company’s stock worth $174,000 after purchasing an additional 4,749 shares during the last quarter. Wedge Capital Management L L P NC bought a new stake in shares of Ironwood Pharmaceuticals during the 3rd quarter worth $1,297,000. Exchange Traded Concepts LLC bought a new stake in Ironwood Pharmaceuticals in the third quarter worth about $279,000. Finally, Inspire Investing LLC increased its stake in shares of Ironwood Pharmaceuticals by 84.8% during the 3rd quarter. Inspire Investing LLC now owns 101,029 shares of the biotechnology company’s stock worth $416,000 after purchasing an additional 46,352 shares during the last quarter.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.